Presenting at a prestigious conference like Digestive Disease Week can significantly raise the profile of Abivax's obefazimod, attracting attention from investors and potentially leading to a positive impact on its stock price. The emphasis on novel preclinical data and the drug's mechanism of action further underscores its potential in a competitive market.